Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
Application of immunotherapeutic modalities changed paradigms in the treatment of hematologic malignancies, with regards to drug manufacturing, treatment protocols, short- and long-term toxicities. FDA-approved therapies, including blinatumomab, tisagenlecleucel, and axicabtagene ciloleucel, target...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2019-06-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://www.atlantis-press.com/article/125907525/view |